Biologics To Dominate 2028 Medicare Negotiation Cycle As Eligibility Expands To Part B

 
• By Cathy Kelly
  
Several Part B immunologics are expected to be targeted for Medicare price negotiation. (Shutterstock)

More from Pricing Debate

More from Medicare